Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy

American Heart Journal

Volumn 154, Issue 3, 2007, Pages 602.e1-602.e5

  Di Napoli, Pericle ^a   Di Giovanni, Paolo ^a   Gaeta, Marta Assunta ^a   D'Apolito, Giuseppina ^c   Barsotti, Antonio ^b  

^a Casa di Cura Villa Pini d'Abruzzo   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547931455     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.033     Document Type: Article

References (26)

1. Kantor P.F., Lucien A., Kozak R., et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 (2000) 580-588
2. Brottier L., Barat J.L., Combe C., et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 11 (1990) 207-212
3. Fragasso G., Piatti P.M., Monti L., et al. Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146 (2003) E18-E25
4. Rosano G.M., Vitale C., Sposato B., et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease. A double-blind, placebo-controlled, study. Cardiovasc Diabetol 2 (2003) 1-9
5. Vitale C., Wajngaten M., Sposato B., et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25 (2004) 1814-1821
6. Di Napoli P., Taccardi A.A., and Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart 91 (2005) 161-165
7. Bouvy M.L., Heerdink E.R., Leufkens H.G., et al. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 89 (2003) 605-609
8. Cowie M.R., Wood D.A., Coats A.J., et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83 (2000) 505-510
9. Scrutinio D., Lagioia R., Ricci A., et al. Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. The role of the New York Heart Association classification, cardiopulmonary exercise testing, two-dimensional echocardiography and Holter monitoring. Eur Heart J 15 (1994) 1089-1095
10. Aaronson K.D., Schwartz J.S., Chen T.M., et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667
11. Ishii J., Nomura M., Nakamura Y., et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 89 (2002) 691-695
12. Hama N., Itoh H., Shirakami G., et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92 (1995) 1558-1564
13. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87 (1993) 464-469
14. Gardner R.S., Ozalp F., Murday A.J., et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
15. Yu C.M., and Sanderson J.E. Plasma brain natriuretic peptide-an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1 (1999) 59-65
16. Koglin J., Pehlivanli S., Schwaiblmair M., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
17. St John Sutton M.G., and Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101 (2000) 2981-2988
18. Sato Y., Kita T., Takatsu Y., et al. Biochemical markers of myocyte injury in heart failure. Heart 90 (2004) 1110-1113
19. Lee L., Horowitz J., and Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J 25 (2004) 634-641
20. Allibardi S., Chierchia S.L., Margonato V., et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat heart. Cardiovasc Drugs Ther 12 (1998) 543-549
21. Renaud J.F. Internal pH, Na+ and Ca++ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1 (1988) 677-686
22. Williams F.M., Tanda K., Kus M., et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 22 (1993) 828-833
23. Di Napoli P., Chierchia S., Taccardi A.A., et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 16 (2007) 228-236
24. Fragasso G., Perseghin G., De Cobelli F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27 (2006) 942-948
25. Fragasso G., Palloshi A., Puccetti P., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48 (2006) 992-998
26. El-Kady T., El-Sabban K., Gabaly M., et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 5 (2005) 271-278